a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Sā¦ (NCT06166836) | Clinical Trial Compass
Active ā Not RecruitingPhase 1/2
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
China140 participantsStarted 2022-10-12
Plain-language summary
This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS G12C mutation.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Men or women aged ā„ 18 years at the time of signing the informed consent form.
ā. Subjects with pathologically confirmed locally advanced or metastatic solid tumors.
ā. Confirmed positive KRAS G12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells or DNA.
ā. Tumor types in different phases and cohorts: 1) Phase 1b: subjects with locally advanced or metastatic solid tumors who have progressed on or failed in standard therapy, and no standard treatment is available. 2) Phase II Cohort A: subjects with locally advanced or metastatic CRC. 3) Phase II Cohort B: subjects with locally advanced or metastatic NSCLC. 4) Phase 2 Cohort C: subjects with other locally advanced or metastatic solid tumors.
ā. Has measurable lesions at baseline according to RECIST 1.1 criteria.
ā. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
ā. Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to the first dose.
Exclusion criteria
ā. Prior KRAS G12C inhibitors treatment.
ā. Have known symptoms of spinal cord compression, instable or symptomatic central nervous system (CNS) metastases, and/or carcinomatous meningitis.
ā. Have a history of stroke or other serious cerebrovascular diseases within 12 months prior to the first dose.
What they're measuring
1
Recommended phase II dose (RP2D) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
Timeframe: Through study completion, approximately 3 years
2
Objective Response Rate (ORR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
Timeframe: Through study completion, approximately 3 years
. Have had interstitial lung disease or any active infection requiring systemic treatment within 14 days prior to the first dose.
ā. Has a history of severe cardiovascular disease such as acute myocardial infarction, severe/unstable angina, QTc prolongation, or poorly controlled hypertension.
ā. Haven't recovered from toxicity due to prior antitumor therapy
ā. Pregnant or lactating women.
ā. Malignant neoplasms other than study disease within 5 years prior to enrollment.